We are live on
!
Find out more
TD Asset Management Portfolio holdings
AUM
$115B
1-Year Est. Return
41.58%
This Fund
S&P 500
This Quarter
Est. Return
+8.84%
1 Year Est. Return
+41.58%
3 Year Est. Return
+119.77%
5 Year Est. Return
+143.7%
10 Year Est. Return
+448.76%
AUM
$82.9B
AUM Growth
+$1.82B
(+2.3%)
Cap. Flow
-$3.2B
Cap. Flow
% of AUM
-3.86%
Top 10 Holdings %
Top 10 Hldgs %
27.48%
Holding
1,503
New
58
Increased
633
Reduced
567
Closed
76
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$256M |
| 2 |
State Street Energy Select Sector SPDR ETF
XLE
|
+$169M |
| 3 |
Eli Lilly
LLY
|
+$156M |
| 4 |
Franco-Nevada
FNV
|
+$115M |
| 5 |
NVIDIA
NVDA
|
+$115M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Canadian Pacific Kansas City
CP
|
+$990M |
| 2 |
Pfizer
PFE
|
+$226M |
| 3 |
Amazon
AMZN
|
+$224M |
| 4 |
Johnson & Johnson
JNJ
|
+$220M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$220M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.76% |
| 2 | Financials | 19.43% |
| 3 | Healthcare | 10.94% |
| 4 | Consumer Discretionary | 8.03% |
| 5 | Communication Services | 7.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
951
Acadia Pharmaceuticals
ACAD
$4.65B
| $2.2M | ﹤0.01% |
116,921
+13,600
| +13% | +$259K |
|
|
HAYN
952
DELISTED
Haynes International, Inc.
HAYN
| $2.19M | ﹤0.01% |
43,660
| – | – |
|
953
Clarivate
CLVT
$1.26B
| $2.18M | ﹤0.01% |
231,992
+4,467
| +2% | +$46K |
|
954
Origin Bancorp
OBK
$1.7B
| $2.17M | ﹤0.01% |
67,560
+7,800
| +13% | +$287K |
|
955
Lantheus
LNTH
$6.58B
| $2.17M | ﹤0.01% |
26,290
+14,600
| +125% | +$942K |
|
956
US Physical Therapy
USPH
$1.15B
| $2.17M | ﹤0.01% |
22,132
-482
| -2% | -$46K |
|
957
Pinnacle Financial Partners Inc
PNFP
$16.5B
| $2.16M | ﹤0.01% |
39,182
-290
| -0.7% | -$20.3K |
|
958
Utz Brands
UTZ
$1.25B
| $2.16M | ﹤0.01% |
131,110
+9,000
| +7% | +$149K |
|
959
Allegiant Air
ALGT
$2.82B
| $2.15M | ﹤0.01% |
23,418
| – | – |
|
960
Liberty Energy
LBRT
$3.23B
| $2.15M | ﹤0.01% |
167,588
-18,000
| -10% | -$266K |
|
961
DaVita
DVA
$14.6B
| $2.14M | ﹤0.01% |
26,445
+12,918
| +95% | +$1.04M |
|
962
Surgery Partners
SGRY
$2.05B
| $2.14M | ﹤0.01% |
61,991
+32,000
| +107% | +$1.04M |
|
963
Universal Health Services
UHS
$10.2B
| $2.13M | ﹤0.01% |
16,737
-2,648
| -14% | -$365K |
|
964
Franklin Resources
BEN
$18.2B
| $2.12M | ﹤0.01% |
78,601
+1,992
| +3% | +$58.2K |
|
965
MYR Group
MYRG
$5.3B
| $2.12M | ﹤0.01% |
16,800
| – | – |
|
|
CMA
966
DELISTED
Comerica
CMA
| $2.12M | ﹤0.01% |
48,729
-16,833
| -26% | -$1.08M |
|
967
Matsons
MATX
$6.46B
| $2.11M | ﹤0.01% |
35,300
-5,700
| -14% | -$367K |
|
968
Alamo Group
ALG
$2.07B
| $2.1M | ﹤0.01% |
11,400
-1,900
| -14% | -$313K |
|
|
KREF
969
KKR Real Estate Finance Trust
KREF
$460M
| $2.1M | ﹤0.01% |
184,100
-82,500
| -31% | -$1.16M |
|
970
First Hawaiian
FHB
$3.44B
| $2.07M | ﹤0.01% |
100,391
-15,451
| -13% | -$389K |
|
|
JUGG
971
DELISTED
Jaws Juggernaut Acquisition Corporation Class A Ordinary Share
JUGG
| $2.05M | ﹤0.01% |
200,000
| – | – |
|
|
BLU
972
DELISTED
BELLUS Health Inc.
BLU
| $2.04M | ﹤0.01% |
283,827
+22,590
| +9% | +$175K |
|
973
Denali Therapeutics
DNLI
$3.84B
| $2.03M | ﹤0.01% |
88,322
-10,887
| -11% | -$300K |
|
|
SAGE
974
DELISTED
Sage Therapeutics
SAGE
| $2.03M | ﹤0.01% |
48,455
| – | – |
|
975
Steven Madden
SHOO
$3.58B
| $2.03M | ﹤0.01% |
56,400
+3,400
| +6% | +$118K |
|
Similar funds
VAM
TD Asset Management's Q1 2023 Portfolio in Review
As of Q1 2023, TD Asset Management held 1,503 positions worth $82.9B, up 2.3% from $81B the previous quarter. Its ten largest holdings account for 27% of the portfolio.
TD Asset Management withdrew a net $3.2B in Q1 2023, closing 76 positions and reducing 567 holdings. Its most notable exit was Canadian Pacific Kansas City, an estimated $990M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 17% a quarter earlier, followed by Financials and Healthcare.
Against the trend, TD Asset Management opened a new position in Novo Nordisk worth $25.2M.
- TD Asset Management's largest Q1 2023 buy was Novo Nordisk: 316,140 shares worth $25.2M.
- TD Asset Management added most to Merck in Q1 2023, an estimated $256M increase.
- TD Asset Management's biggest Q1 2023 reduction was Pfizer, cutting an estimated $226M.
- TD Asset Management fully exited Canadian Pacific Kansas City in Q1 2023, selling an estimated $990M.
- TD Asset Management's ten largest holdings make up 27% of its $82.9B portfolio in Q1 2023.
- TD Asset Management opened 58 new positions and closed 76 in Q1 2023.
- TD Asset Management's portfolio value rose 2.3% quarter-over-quarter to $82.9B.
Based on TD Asset Management's 13F filing for Q1 2023, filed 10 May 2023.